Brandy German
Family · Angola, INNPI 1457623928
Payments from drug & device makers
Across 213 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$897
- AbbVie$505
- GSK$339
- Novo Nordisk$319
- Lilly USA, LLC$298
- Boehringer Ingelheim$231
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,969100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $897 |
| AbbVie | 39 | $505 |
| GSK | 25 | $339 |
| Novo Nordisk | 18 | $319 |
| Lilly USA, LLC | 10 | $298 |
| Boehringer Ingelheim | 14 | $231 |
| Axsome Therapeutics, Inc. | 6 | $194 |
| UCB, Inc. | 1 | $124 |
| Dexcom, Inc. | 7 | $119 |
| Therapeuticsmd, Inc. | 1 | $100 |
| Amarin Pharma, Inc. | 6 | $100 |
| Exact Sciences | 6 | $96 |
| Abbott | 4 | $67 |
| Astellas Pharma US Inc | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Johnson & Johnson | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Corium, LLC | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Amgen | 2 | $28 |
| Philips North America LLC | 1 | $20 |
| Bayer | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Pfizer | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Organogenesis Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,969 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $136,056 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $99,567 |
| FarxigaDapagliflozin Propanediol | 67 | $79,678 |
| MounjaroTirzepatide | 38 | $46,502 |
| TrulicityDulaglutide | 21 | $38,332 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $30,984 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $29,949 |
| RybelsusSemaglutide | 18 | $26,790 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $25,911 |
| EliquisApixaban | 21 | $24,025 |
| JardianceEmpagliflozin | 19 | $23,935 |
| XareltoRivaroxaban | 13 | $21,007 |
| VascepaIcosapent Ethyl | 19 | $13,400 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $12,101 |
| JanuviaSitagliptin Phosphate | 12 | $8,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $319 | $162,846118 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $339 | $142,652166 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $897 | $105,58983 claims |
| Lilly USA, LLCMounjaro, Trulicity | $298 | $84,83459 claims |
| PfizerEliquis | $17 | $24,02521 claims |
| Boehringer IngelheimJardiance | $231 | $23,93519 claims |
| Johnson & JohnsonXarelto | $49 | $21,00713 claims |
| MerckJanuvia | $12 | $8,51712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Angola
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.